NCT03824522View on ClinicalTrials.gov

Post Marketing Surveillance Study for ADYNOVATE in South Korea

CompletedOBSERVATIONAL
Enrollment

341

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

January 5, 2024

Study Completion Date

January 5, 2024

Conditions
Hemophilia A
Interventions
BIOLOGICAL

ADYNOVATE

Pegylated recombinant human factor VIII

Trial Locations (8)

41404

Kyungpook National University Chilgok Hospital, Daegu

41944

Kyungpook National University Hospital, Daegu

42472

Daegu Catholic University Medical Center, Daegu

44033

Ulsan University Hospital, Ulsan

03722

Severance Hospital Yonsei University Health System, Seoul

05278

Kyung Hee University Hospital at Gangdong, Seoul

05538

Kim Hugh Chul Internal Medicine, Seoul

06641

Korea Hemophilia Foundation (Seoul), Seoul

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
collaborator

Takeda Pharma Korea Co. Ltd.

UNKNOWN

lead

Takeda

INDUSTRY

NCT03824522 - Post Marketing Surveillance Study for ADYNOVATE in South Korea | Biotech Hunter | Biotech Hunter